Results 151 to 160 of about 2,261 (229)

Hansen's disease patient in Ohio successfully treated with a monthly rifampin, minocycline, and moxifloxacin regimen: a case report. [PDF]

ASM Case Rep
Sankovic DE, Hubal AL, Alhajj MA, Anderson NW, Cherian S, Gundelly P, Ransom EM.   +6 more
europepmc   +1 more source

The DNA/RNA autophagy protein SIDT2 as a novel neuropathological hallmark in Huntington disease

Brain Pathology, EarlyView.
SIDT2‐immunoreactive inclusions are observed in the striatum, cerebral cortex, and hypothalamus in HD cases with different Vonsattel grades, and the frequency of SIDT2‐immunoreactive inclusions is associated with longer CAG repeats in the huntingtin gene.
Sanaz Gabery, Sofia Bergh, Chrisovalantou Huridou, Rachel Y. Cheong, Barbara Baldo, Paul Günther Scheunemann, Marie‐Louisa Schoebel, Linda Holmquist Mengelbier, Elisabet Englund, Catriona McLean, Carsten Saft, Deniz Kirik, Maria Björkqvist, Glenda Halliday, Elisabeth Petrasch‐Parwez, Huu Phuc Nguyen, Jonasz Jeremiasz Weber, Åsa Petersén   +17 more
wiley   +1 more source

Hansen's Disease in Ecuador: Current Status, Knowledge Gaps, and Research Priorities: A Literature Review. [PDF]

Pathogens
Calvopiña M, Izquierdo-Condoy JS, Ortiz-Prado E, Vasconez-Gonzalez J, Vaca L, Guamán E.   +5 more
europepmc   +1 more source

IgE And IgG Antibody Responses to α‐Gal and Association With Carotid Stenosis in Swedish Patients

Allergy, EarlyView.
Marija Perusko, Danijela Apostolovic, Jeanette Grundström, Malin Kronqvist, Mirjana Radomirovic, Anna Smed‐Sörensen, Ulf Hedin, Marianne van Hage   +7 more
wiley   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Navigating diagnostic and therapeutic challenges in ocular manifestations of Hansen's disease and trachoma: A narrative review. [PDF]

Indian J Ophthalmol
Gurnani B, Kaur K, Savla HR, Prajjwal P, Pentapati SSK, Kutikuppala LVS.   +5 more
europepmc   +1 more source

Targeting protein–protein interactions with reversible covalent modalities: Non‐cysteine chemistries

British Journal of Pharmacology, EarlyView.
Abstract Protein–protein interactions (PPIs) are central to diverse cellular functions, and represent a rapidly expanding class of therapeutic targets. Advancements in covalent drug design have enabled small‐molecule drugs to overcome challenges associated with engaging these targets, such as limited durations of action and difficult‐to‐drug (expansive,
Ruchira Basu, Steven Fletcher
wiley   +1 more source

Experiences of social stigma of people living with Hansen's disease in Brazil: silencing, secrets and exclusion. [PDF]

Int Health
Souza GC, de Oliveira PS, de Araujo PN, Dos Santos FL, da Silva JP, Santos KDS, Fortuna CM.   +6 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Strengthening epidemiological surveillance in primary healthcare to combat Hansen's disease: reflections on the disease in the Brazilian context, 2025. [PDF]

Epidemiol Serv Saude
Elidio GA, Guilhem DB.
europepmc   +1 more source